精品人妻无码一区二区三区软件 ,麻豆亚洲AV成人无码久久精品,成人欧美一区二区三区视频,免费av毛片不卡无码

您現(xiàn)在的位置是:首頁(yè)SCI期刊Expert Review of Gastroenterology & Hepatology(胃腸病學(xué)和肝病學(xué)專(zhuān)家評(píng)論)
Expert Review of Gastroenterology & Hepatology

Expert Review of Gastroenterology & Hepatology SCIE

胃腸病學(xué)和肝病學(xué)專(zhuān)家評(píng)論

1747-4124

醫(yī)學(xué)

No

EXPERT REV GASTROENT

0

101

ENGLAND

http://www.tandfonline.com/toc/ierh20/current

較慢,6-12周審稿時(shí)間

3區(qū)中科院分區(qū)

較易平均錄用比例

2.991影響因子

胃腸肝病學(xué)小學(xué)科

SCI三劍客

中文簡(jiǎn)介

全世界胃腸道疾病的巨大健康和經(jīng)濟(jì)負(fù)擔(dān)使得人們必須高度重視新療法的病因、流行病學(xué)、預(yù)防、診斷、治療和發(fā)展。到上個(gè)世紀(jì)末,我們已經(jīng)看到了巨大的進(jìn)步,無(wú)論是在可視化疾病的技術(shù)上,還是在胃潰瘍等領(lǐng)域的治療上,H2拮抗劑的出現(xiàn),然后質(zhì)子泵抑制劑的出現(xiàn),都清楚地說(shuō)明了醫(yī)學(xué)的進(jìn)步如何能使患者受益。然而,專(zhuān)家們面臨著來(lái)自各種病因的疾病的持續(xù)挑戰(zhàn)。在相關(guān)的肝病領(lǐng)域,僅在美國(guó),肝病和肝硬化是25-64歲成年人的第七大死因。具體來(lái)說(shuō),乙型肝炎的傳染性是艾滋病病毒的100倍,目前全世界有5%的人口受到感染。隨著科學(xué)界和臨床界用新技術(shù)、新的治療和診斷方式以及在分子水平上對(duì)疾病的新理解來(lái)應(yīng)對(duì)這些挑戰(zhàn),科學(xué)文獻(xiàn)正在爆炸性地激增。胃腸病和肝病專(zhuān)家評(píng)論(ISSN1747-4124)提供了最新研究和臨床進(jìn)展的全面報(bào)道。該雜志關(guān)注我們對(duì)影響胃腸道和肝臟疾病的病理、生化和生理學(xué)理解的最新進(jìn)展,以及預(yù)防、診斷和干預(yù)策略的最新發(fā)展。文章涵蓋以下關(guān)鍵領(lǐng)域:?對(duì)消化系統(tǒng)及其相關(guān)器官疾病的病理、生化和生理學(xué)理解的最新進(jìn)展?研究策略的發(fā)展,如放射學(xué)、內(nèi)窺鏡檢查、膽胰造影、結(jié)腸鏡檢查和肝活檢?分子診斷和生物標(biāo)記研究進(jìn)展?藥理學(xué)方法和新興治療學(xué)的最新進(jìn)展?藥物安全性?疾病特異性綜述,包括消化癌、肝炎感染、肝硬化、炎癥性腸病、功能性胃腸道疾病、膽道和膽囊疾病的報(bào)道。?針對(duì)診斷和問(wèn)題,如吸收、營(yíng)養(yǎng)和生長(zhǎng),對(duì)兒童消化系統(tǒng)疾病進(jìn)行最佳管理。?心理社會(huì)方面?藥理學(xué)和結(jié)果研究,輔以成本效益分析專(zhuān)家評(píng)審的形式是獨(dú)特的,因?yàn)樗囵B(yǎng)了一種前瞻性的思維方式。每一次審查都提供了對(duì)關(guān)鍵領(lǐng)域當(dāng)前理解的完整概述,并通過(guò)以下關(guān)鍵部分加以補(bǔ)充:專(zhuān)家意見(jiàn)-對(duì)本文中所述數(shù)據(jù)的個(gè)人觀點(diǎn),對(duì)未來(lái)可能重要的發(fā)展的討論,以及隨著進(jìn)一步研究產(chǎn)生更詳細(xì)的結(jié)果,研究的途徑可能變得令人興奮。文章重點(diǎn)——作者最關(guān)鍵點(diǎn)的執(zhí)行摘要所有評(píng)審都要接受同行評(píng)審,至少要進(jìn)行三次獨(dú)立評(píng)審。胃腸病和肝病專(zhuān)家評(píng)審為本專(zhuān)業(yè)所有專(zhuān)業(yè)人員提供了一個(gè)系統(tǒng)、權(quán)威的分析和辯論的平臺(tái)。

https://mc.manuscriptcentral.com/erh

英文簡(jiǎn)介

The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology. In the related field of hepatology, liver disease and cirrhosis are the seventh leading cause of death among adults between 25–64 years of age in the USA alone. Specifically, Hepatitis B is 100 times more infectious than the AIDS virus and currently 5% of the population, worldwide, is infected. As the scientific and clinical communities address these challenges with new technologies, new therapeutic and diagnostic modalities and new understanding of disease at the molecular level, the scientific literature is proliferating explosively. Expert Review of Gastroenterology & Hepatology (ISSN 1747-4124) provides comprehensive coverage of state-of-the-art research and clinical advancements in the field as they occur. The journal focuses on the latest advances in our pathological, biochemical and physiological understanding of the diseases affecting the gastrointestinal tract and liver, in addition to up-to-the-minute developments in strategies for prevention, diagnosis and intervention. Article coverage includes the following key areas: ? Latest advances in pathological, biochemical and physiological understanding of the diseases of the digestive system and its associated organs ? Developments in investigative strategies; such as radiology, endoscopy, cholangiopancreatography, colonoscopy and liver biopsy ? Advances in molecular diagnosis and biomarker research ? Recent developments in pharmacological approaches and emerging therapeutics ? Drug safety ? Disease-specific reviews, including coverage of digestive cancers, hepatitis infections, liver cirrhosis, inflammatory bowel disease, functional gastrointestinal disorder, and biliary and gall bladder disease ? Optimal management of pediatric digestive diseases, with regard to diagnosis and issues, such as absorption, nutrition and growth ? Psychosocial aspects ? Pharmacoeconomics and outcomes research, supplemented by cost–benefit analysis The Expert Review format is unique in that it fosters a forward-thinking approach. Each review provides a complete overview of current understanding in a key area, which is augmented by the following key sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points All reviews are subject to peer review, with a minimum of three independent evaluations. Expert Review of Gastroenterology & Hepatology provides a forum for systematic, authoritative analysis and debate for all professionals within this specialty.

中科院分區(qū)(數(shù)據(jù)版本:2021年12月最新升級(jí)版)

大類(lèi)學(xué)科 分區(qū) 小類(lèi)學(xué)科 分區(qū) Top期刊 綜述期刊
醫(yī)學(xué) 3區(qū) GASTROENTEROLOGY & HEPATOLOGY 胃腸肝病學(xué) 3區(qū)

JCR分區(qū)

JCR分區(qū)等級(jí) JCR所屬學(xué)科 分區(qū) 影響因子
Q2 GASTROENTEROLOGY & HEPATOLOGY Q2 4.095

CiteScore數(shù)值

CiteScore SJR SNIP 學(xué)科類(lèi)別 分區(qū) 排名 百分位
6.30 0.923 1.185 大類(lèi):Medicine 小類(lèi):Gastroenterology Q1 29 / 149

80%

大類(lèi):Medicine 小類(lèi):Hepatology Q2 24 / 70

66%

SCI服務(wù)流程
服務(wù)流程
常見(jiàn)問(wèn)題
Q&A
關(guān)于電子電氣領(lǐng)域的SCI期刊是有不少的,但更多作者在選擇時(shí)尤為要注意的是其是否有預(yù)警風(fēng)險(xiǎn),畢竟存在預(yù)警風(fēng)險(xiǎn)的期
sci小修以后二審快嗎? 這個(gè)主要還是根據(jù)作者自身稿件以及期刊具體情況而定,二審的快慢是有很多因素決定的,比如作
sci論文對(duì)評(píng)職有很高的加分,這也是很多作者都非常關(guān)心的,因此也是有不少人問(wèn), 評(píng)職稱sci論文算幾分? 其實(shí)這也并沒(méi)
生物學(xué)方向的SCI期刊在選擇上也是眾多的,尤其是根據(jù)分區(qū)來(lái)看,不少作者更為傾向的還是三區(qū)刊物的,畢竟有著一定的

影響因子趨勢(shì)圖

H-index

影響因子 h-index Gold OA文章占比 研究類(lèi)文章占比 OA開(kāi)放訪問(wèn) 平均審稿速度
4.095 41 5.46% 41.86% 未開(kāi)放 較慢,6-12周

自引率趨勢(shì)圖

SCI服務(wù)明細(xì)

醫(yī)學(xué)方向的SCI期刊推薦
R&J
大類(lèi)學(xué)科同領(lǐng)域優(yōu)質(zhì)期刊 大類(lèi)學(xué)科 小類(lèi)學(xué)科 影響因子 分區(qū) ISSN
ACTA GASTRO-ENTEROLOGICA BELGICA 醫(yī)學(xué) 胃腸肝病學(xué) 0.541 N/A 1784-3227
ALIMENTARY PHARMACOLOGY & THERAPEUTICS 醫(yī)學(xué) 胃腸肝病學(xué) 7.731 N/A 0269-2813
AMERICAN JOURNAL OF GASTROENTEROLOGY 醫(yī)學(xué) 胃腸肝病學(xué) 10.241 N/A 0002-9270
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 醫(yī)學(xué) 胃腸肝病學(xué) 3.729 N/A 0193-1857
Annals of Hepatology 醫(yī)學(xué) 胃腸肝病學(xué) 1.895 N/A 1665-2681
BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY 醫(yī)學(xué) 胃腸肝病學(xué) N/A N/A 1521-6918
BMC GASTROENTEROLOGY 醫(yī)學(xué) 胃腸肝病學(xué) 2.252 N/A 1471-230X
Clinical Gastroenterology and Hepatology 醫(yī)學(xué) 胃腸肝病學(xué) 7.958 1區(qū) 1542-3565
Clinics in Liver Disease 醫(yī)學(xué) 胃腸肝病學(xué) 5.233 N/A 1089-3261
Colorectal Disease 醫(yī)學(xué) 胃腸肝病學(xué) 2.997 N/A 1462-8910
在國(guó)際sci上發(fā)表期刊論文,對(duì)于國(guó)內(nèi)作者來(lái)說(shuō)是非常有好處的,除了證明自身學(xué)術(shù)水平外,還能夠促進(jìn)學(xué)術(shù)交流,尤其是...
在醫(yī)學(xué)領(lǐng)域中的生殖醫(yī)學(xué)這一方向所涉及的期刊數(shù)量是不少的,尤其是被SCI所收錄的,大都是非常優(yōu)秀的刊物。就如這里...
論文發(fā)表醫(yī)學(xué)SCI論文是一個(gè)系統(tǒng)且復(fù)雜的過(guò)程,作者需要經(jīng)過(guò)多次修改和完善,以確保論文符合sci期刊要求。以下是為大...
SCI所收錄的檢驗(yàn)醫(yī)學(xué)期刊不在少數(shù),很多作者在選擇時(shí)可以根據(jù)其期刊影響因子的高低,來(lái)與自身實(shí)際需求以及實(shí)力水平...
所謂的破格評(píng)審也就是對(duì)不達(dá)規(guī)定學(xué)歷要求或不滿相應(yīng)的任現(xiàn)職年限,若業(yè)績(jī)、貢獻(xiàn)特別突出者,可根據(jù)相應(yīng)的破格條件破...
1:Journal of Crohns Liver, Pancreas and Biliary Tract; Case Reports; Special Reports and Reviews; and a section on Clinical Challenges which presents more in-...
由于最新的中科院分區(qū)表已出,其中有不少刊物是有所變化的,所以這里有作者問(wèn)的 最新胃腸肝病學(xué)SCI醫(yī)學(xué)期刊 ,那么...

發(fā)現(xiàn)心儀選題請(qǐng)?zhí)顔?/b>

獲取發(fā)表周期短、審稿速度快容易錄用的期刊